Scarica l'app Stockscreener
4.33
2.91%
-0.13
Dopo l'orario di chiusura:
4.30
-0.03
-0.69%
Precedente Chiudi:
$4.46
Aprire:
$4.46
Volume 24 ore:
512.59K
Relative Volume:
1.13
Capitalizzazione di mercato:
$338.29M
Reddito:
$351.37M
Utile/perdita netta:
$-174.01M
Rapporto P/E:
-2.0918
EPS:
-2.07
Flusso di cassa netto:
$-126.94M
1 W Prestazione:
+7.71%
1M Prestazione:
+19.94%
6M Prestazione:
+23.36%
1 anno Prestazione:
+39.23%
Intervallo 1D:
$4.265
$4.50
Intervallo di 1 settimana:
$3.91
$4.50
Portata 52W:
$2.455
$4.50
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
Nome
Atea Pharmaceuticals Inc
Settore
Industria
Telefono
857-204-8109
Indirizzo
225 FRANKLIN STREET, BOSTON
Compare AVIR vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AVIR
Atea Pharmaceuticals Inc
|
4.33 | 348.45M | 351.37M | -174.01M | -126.94M | -2.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-13 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-08-10 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-01-06 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-18 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-10-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-25 | Iniziato | Evercore ISI | Outperform |
| 2020-11-24 | Iniziato | JP Morgan | Overweight |
| 2020-11-24 | Iniziato | Morgan Stanley | Overweight |
| 2020-11-24 | Iniziato | William Blair | Outperform |
Mostra tutto
Atea Pharmaceuticals Inc Borsa (AVIR) Ultime notizie
Published on: 2026-02-08 21:54:48 - baoquankhu1.vn
Atea Pharmaceuticals (NASDAQ:AVIR) Shares Down 2%Here's What Happened - MarketBeat
Atea Pharmaceuticals (NASDAQ:AVIR) Trading Down 2%Time to Sell? - MarketBeat
Atea Pharmaceuticals (NASDAQ:AVIR) Shares Down 2% – Here’s What Happened - Defense World
Street Watch: Is Atea Pharmaceuticals Inc attractive for institutional investorsIndex Update & Safe Capital Growth Stock Tips - baoquankhu1.vn
Aug Closing: Is Atea Pharmaceuticals Inc still a buy after recent gains2025 Historical Comparison & Risk Controlled Swing Alerts - baoquankhu1.vn
Aug Sectors: Will BIIB benefit from sector rotationJuly 2025 Final Week & Risk Managed Investment Entry Signals - baoquankhu1.vn
Will Atea Pharmaceuticals Inc. face regulatory challengesDividend Hike & Weekly Breakout Opportunity Watchlist - mfd.ru
Risk Hedge: Can Atea Pharmaceuticals Inc stock double in the next yearJuly 2025 Retail & Technical Pattern Based Buy Signals - baoquankhu1.vn
Update Report: Is Atea Pharmaceuticals Inc stock undervalued right now2025 Key Highlights & Accurate Intraday Trade Tips - baoquankhu1.vn
Aug EndMonth: Can The AZEK Company Inc stock double in the next yearJuly 2025 WrapUp & Real-Time Market Trend Scan - baoquankhu1.vn
Institutional Investors Are Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Biggest Bettors and Were Rewarded After Last Week's US$56m Market Cap Gain - 富途牛牛
Can Atea Pharmaceuticals Inc expand into new marketsEarnings Recap Report & Risk Managed Trade Strategies - baoquankhu1.vn
Spotlight On Atea Pharmaceuticals And 2 Other Noteworthy Penny Stocks - Yahoo Finance
Atea Pharmaceuticals Highlights Phase 3 HCV Timeline, Unveils New Hepatitis E Candidate AT-587 at JPMorgan Conference - MarketBeat
Is Atea Pharmaceuticals Inc. still a buy after recent gainsBlue Chip Stock Analysis & Daily Tips From Top Market Analysts - bollywoodhelpline.com
JPM26: Atea Pharmaceuticals outlines HCV strategy centred on short-duration regimens - Pharmaceutical Technology
Dip Buying: Can Atea Pharmaceuticals Inc stock double in the next year2025 Bull vs Bear & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Atea Pharmaceuticals (AVIR) and Penumbra (PEN) - The Globe and Mail
Buyout Rumor: Is Atea Pharmaceuticals Inc a momentum stockTrend Reversal & Expert Curated Trade Setups - baoquankhu1.vn
Wall Street Recap: Will Atea Pharmaceuticals Inc face regulatory challengesTrade Volume Report & Long-Term Investment Growth Plans - baoquankhu1.vn
Options Flow: Will Atea Pharmaceuticals Inc stock maintain dividend yieldJuly 2025 Patterns & Smart Money Movement Tracker - Bộ Nội Vụ
Bullish Atea Pharmaceuticals Insiders Loaded Up On US$5.40m Of Stock - Yahoo Finance
How Atea Pharmaceuticals Inc. stock performs in weak economyJuly 2025 Technicals & Entry Point Confirmation Alerts - Улправда
What is the fair value of Atea Pharmaceuticals Inc. stock nowEarnings Miss & Community Consensus Stock Picks - ulpravda.ru
Risk Off: Will Atea Pharmaceuticals Inc stock attract more institutional investorsTrade Exit Report & Risk Adjusted Buy/Sell Alerts - Bộ Nội Vụ
Atea Pharmaceuticals to highlight strategic priorities for FY26 - Yahoo Finance
Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference - Sahm
Will Atea Pharmaceuticals Inc. stock attract more institutional investorsTrade Ideas & Safe Capital Growth Stock Tips - ulpravda.ru
Why Atea Pharmaceuticals Inc. stock is popular among millennials2025 Trading Volume Trends & Community Consensus Trade Alerts - Улправда
Will Atea Pharmaceuticals Inc. stock deliver strong dividend growthGlobal Markets & Precise Buy Zone Identification - ulpravda.ru
Atea Pharmaceuticals Highlights 2026 Strategic Priorities - TradingView — Track All Markets
Atea Pharmaceuticals Advances Phase 3 Trials for HCV Treatment Regimen, Anticipates Significant Milestones in 2026 - Quiver Quantitative
New hepatitis C and E treatments move toward key human clinical trials in 2026 - Stock Titan
Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Is Atea Pharmaceuticals Inc. stock supported by strong cash flows2026 world cup usa national team qualification star players pressing system winner prediction breakdown - ulpravda.ru
Critical Survey: Atea Pharmaceuticals (NASDAQ:AVIR) vs. Regeneron Pharmaceuticals (NASDAQ:REGN) - Defense World
What analysts say about Atea Pharmaceuticals Inc stockTrading Volume Trends & Build a Smarter Portfolio Right Now - earlytimes.in
What drives Atea Pharmaceuticals Inc stock priceWeekly Market Snapshot & Access Free Risk Analysis Before You Invest - earlytimes.in
Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price Down 1.4% – Here’s What Happened - Defense World
Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price Down 1.4%Here's What Happened - MarketBeat
Rapt Therapeutics (NASDAQ:RAPT) & Atea Pharmaceuticals (NASDAQ:AVIR) Head-To-Head Contrast - Defense World
Atea Pharmaceuticals: Potential Best-In-Class HCV Cure With Pivotal Readouts In 2026 - Seeking Alpha
Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus - Sahm
Is Atea Pharma Moving BEYOND The Virus And FORWARD To Breakthroughs? - RTTNews
Atea Pharmaceuticals Completes Enrollment in North American Phase 3 Trial of Hepatitis C Treatment - marketscreener.com
Atea Pharmaceuticals Completes Enrollment in C-BEYOND Phase 3 Trial for HCV Treatment, Anticipates Topline Results in Mid-2026 - Quiver Quantitative
Atea Pharmaceuticals Completes Patient Enrollment In North American Phase 3 Trial Evaluating Regimen Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus - TradingView — Track All Markets
Atea Pharmaceuticals Completes Patient Enrollment in North - GlobeNewswire
Published on: 2025-12-21 17:47:39 - Улправда
Why analysts upgrade Atea Pharmaceuticals Inc. stockEarnings Overview Report & Stepwise Swing Trade Plans - Улправда
Atea Pharmaceuticals Inc Azioni (AVIR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):